AstraZeneca PLC Website

AstraZeneca PLC

LSE-AZN

Basic

  • Market Cap

    £192.2B

  • EV

    £213.36B

  • Shares Out

    1,550.26M

  • Revenue

    $47.61B

  • Employees

    89,900

Margins

  • Gross

    82.5%

  • EBITDA

    33.19%

  • Operating

    23.53%

  • Pre-Tax

    15.62%

  • Net

    13.3%

  • FCF

    17.15%

Returns (5Yr Avg)

  • ROA

    3.53%

  • ROTA

    -118.54%

  • ROE

    12.59%

  • ROCE

    9.89%

  • ROIC

    7.98%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    £136.65

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $8,021M

  • Net Debt

    $26.67B

  • Debt/Equity

    0.93

  • EBIT/Interest

    8.84

Growth (CAGR)

  • Rev 3Yr

    19.96%

  • Rev 5Yr

    16.27%

  • Rev 10Yr

    6.32%

  • Dil EPS 3Yr

    10.14%

  • Dil EPS 5Yr

    16.34%

  • Dil EPS 10Yr

    9.52%

  • Rev Fwd 2Yr

    10.14%

  • EBITDA Fwd 2Yr

    21.8%

  • EPS Fwd 2Yr

    13.5%

  • EPS LT Growth Est

    13.45%

Dividends

  • Yield

  • Payout

    70.95%

  • DPS

    $2.9

  • DPS Growth 3Yr

    1.18%

  • DPS Growth 5Yr

    0.7%

  • DPS Growth 10Yr

    0.35%

  • DPS Growth Fwd 2Yr

    5.76%

Select a metric from the list below to chart it

Dec '14

Dec '15

Dec '16

Dec '17

Dec '18

Dec '19

Dec '20

Dec '21

Dec '22

Dec '23

LTM

Dec '24 (E)

Dec '25 (E)

Dec '26 (E)

Operating Revenues

24,384

26,617

37,417

44,351

45,811

47,611

Other Revenues, Total

Total Revenues

24,384

26,617

37,417

44,351

45,811

47,611

Total Revenues % Chg.

10.4%

9.2%

40.6%

18.5%

3.3%

8.6%

Cost of Goods Sold, Total

4,848

5,246

12,005

8,619

8,040

8,333

Gross Profit

19,536

21,371

25,412

35,732

37,771

39,278

Selling General & Admin Expenses, Total

11,438

11,586

14,673

17,422

18,025

18,365

R&D Expenses

5,349

5,901

8,049

9,529

10,299

10,662

Other Operating Expenses

-319

-486

-207

-231

-987

-952

Other Operating Expenses, Total

16,468

17,001

22,515

26,720

27,337

28,075

Operating Income

3,068

4,370

2,897

9,012

10,434

11,203

Interest Expense, Total

-780

-738

-776

-917

-1,219

-1,267

Interest And Investment Income

145

77

43

81

301

334

Net Interest Expenses

-635

-661

-733

-836

-918

-933

Income (Loss) On Equity Invest.

-116

-27

-64

-5

-12

-25

Currency Exchange Gains (Loss)

-30

-34

-20

-16

-34

-34

Other Non Operating Income (Expenses)

-542

-487

-478

-370

-292

-292

EBT, Excl. Unusual Items

1,745

3,161

1,602

7,785

9,178

9,919

Restructuring Charges

-347

-251

-1,283

-717

-467

-662

Merger & Related Restructuring Charges

-3,571

-137

-137

Gain (Loss) On Sale Of Investments

776

Gain (Loss) On Sale Of Assets

1,222

1,055

509

216

292

51

Asset Writedown

-1,036

-252

-2,069

-241

-434

-163

Legal Settlements

-610

9

-48

-789

-1,013

-1,013

Other Unusual Items

574

194

248

-182

-520

-558

EBT, Incl. Unusual Items

1,548

3,916

-265

2,501

6,899

7,437

Income Tax Expense

321

772

-380

-792

938

1,100

Earnings From Continuing Operations

1,227

3,144

115

3,293

5,961

6,337

Minority Interest

108

52

-3

-5

-6

-6

Net Income

1,335

3,196

112

3,288

5,955

6,331

Net Income to Common Incl Extra Items

1,335

3,196

112

3,288

5,955

6,331

Net Income to Common Excl. Extra Items

1,335

3,196

112

3,288

5,955

6,331

Total Shares Outstanding

1,312.1

1,312.7

1,549.4

1,549.8

1,550.2

1,549

Weighted Avg. Shares Outstanding

1,301

1,312

1,418

1,548

1,549

1,549

Weighted Avg. Shares Outstanding Dil

1,301

1,313

1,427

1,560

1,562

1,562

EPS

1

2.4

0.1

2.1

3.8

4.1

EPS Diluted

1

2.4

0.1

2.1

3.8

4

EBITDA

5,575

6,990

6,701

13,944

15,010

15,803

Effective Tax Rate

20.7%

19.7%

143.4%

-31.7%

13.6%

14.8%